Gain Therapeutics Inc GANX
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-03-18 |
| Shares Out. | 42,650,000 |
| Website | gaintherapeutics.com/ ↗ |
| Phone | 13015001556 |
| Employees | 21 |
| Net Income | -$5.6M |
| Total Assets | $18.7M |
| Total Liabilities | $4.7M |
| Equity | $14.0M |
About Gain Therapeutics Inc
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
Gain Therapeutics Inc is a publicly traded company under the ticker symbol GANX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-07-01)